Biogen Inc. Stock
€177.80
Your prediction
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 1.000% | -1.244% | 1.103% | 57.624% | 18.652% | -28.994% | -35.638% |
| BioMarin Pharmaceutical Inc. | 0.620% | 0.192% | 3.366% | 2.675% | 2.554% | -33.941% | -20.232% |
| Zoetis Inc. A | 0.920% | -0.927% | -3.747% | -49.015% | -38.264% | -60.501% | -61.677% |
| Elanco Animal Health Inc. | -2.070% | -3.097% | 3.693% | 75.340% | 13.319% | 100.917% | -29.378% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen says its Phase 2 CELIA study of tau-targeting Alzheimer’s drug diranersen missed the main dose-response
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Biogen (NASDAQ: BIIB) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth depends on the life of a patent. Once a
